The Brazilian pharmaceutical company that plans to produce Russia’s coronavirus vaccine Sputnik V said it expects to overcome regulatory obstacles in “two or three” days to obtain authorization to make and sell the shot in Brazil.

After a 5-hour video conference with União Quimica executives and members of Moscow’s Gamaleya Institute, Brazil’s health regulator Anvisa said there was still information missing before it could approve the vaccine, Reuters reported.

“Anvisa still requires a few more things from Moscow on their Phase 3 trials and I expect to deliver those in two or three days,” the company’s chief executive and owner Fernando Marques said.